Mersana Therapeutics (MRSN) CFO DeSchuytner sold 8,470 shares for $4,913 at $0.58 under a 10b5-1 plan
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Brian DeSchuytner (SVP, COO & CFO at Mersana Therapeutics Inc., MRSN) reported that they sold 8,470 shares for $4,913 at $0.58, and acquired 20,833 shares between Jan 15, 2025 and Jan 16, 2025. After these transactions the filing shows 121,393 shares held directly.
- Reporting person
- DeSchuytner Brian
- Role
- SVP, COO & CFO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | Exercise or conversion of a derivative (M) | Common Stock1, 2 | +20,833 | - | - | 129,863 direct |
| Jan 16, 2025 | Open-market sale (S) | Common Stock3, 4 | -8,470 | $0.58 | $4,913 | 121,393 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | Exercise or conversion of a derivative (M) | Restricted Stock UnitOn 20,833 Common Stock5, 6, 7 | -20,833 | - | - | 43,750 direct |
| Jan 15, 2025 | Grant or award (A) | Stock Option (Right to Buy)On 281,250 Common Stock8 | +281,250 | - | - | 281,250 direct |
| Jan 15, 2025 | Grant or award (A) | Restricted Stock UnitOn 62,500 Common Stock5, 9 | +62,500 | - | - | 62,500 direct |
Holdings before and after
- Common Stock: 109,030 to 121,393 direct
- Restricted Stock Unit: 6,250 to 62,500 direct
- Stock Option (Right to Buy): 0 to 281,250 direct
Footnotes from the filing
- 1. Represents shares of common stock received upon vesting of a portion of the restricted stock units ( RSUs ) awarded to the Reporting Person on January 15, 2021.
- 2. Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2024.
- 3. Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic sell to cover transaction that did not represent a discretionary trade by the Reporting Person.
- 4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 5. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- 6. Fully vested as of January 15, 2025.
- 7. 25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years.
- 8. The option shall vest in equal quarterly installments over four years from the date of grant.
- 9. The RSUs shall vest in equal annual installments over four years from the date of grant.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did DeSchuytner report in this MRSN Form 4?
Brian DeSchuytner (SVP, COO & CFO at Mersana Therapeutics Inc., MRSN) reported that they sold 8,470 shares for $4,913 at $0.58, and acquired 20,833 shares between Jan 15, 2025 and Jan 16, 2025. After these transactions the filing shows 121,393 shares held directly.
How many MRSN shares does DeSchuytner hold after this filing?
The filing shows 121,393 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this MRSN insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for MRSN
Earlier insider filings at MRSN
- Jan 18, 2025SVP, Chief Legal Officer Carvajal Alejandra converted options into 12,500 shares and sold $2,956 worth of shares (5,096 units at $0.58), increasing direct ownership by 10% to 78,296 units (SEC Form 4)
- Jan 18, 2025SVP, Chief Development Officer Bala Mohan converted options into 14,583 shares and sold $3,445 worth of shares (5,939 units at $0.58), increasing direct ownership by 14% to 68,872 units (SEC Form 4)
- Jan 16, 2025Director Protopapas Anna converted options into 16,750 shares and sold $3,900 worth of shares (6,191 units at $0.63), increasing direct ownership by 7% to 155,428 units (SEC Form 4)
- Jan 16, 2025VP, Chief Accounting Officer Mandelia Ashish converted options into 4,783 shares and sold $1,128 worth of shares (1,791 units at $0.63), increasing direct ownership by 6% to 52,388 units (SEC Form 4)
- Jan 16, 2025SVP, Chief Sci.&Tech. Officer Lowinger Timothy B sold $1,130 worth of shares (1,794 units at $0.63) and converted options into 4,792 shares, increasing direct ownership by 1% to 245,930 units (SEC Form 4)
Quantisnow market dataNASDAQ
MRSN
Mersana Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for MRSN
Full MRSN profile on Quantisnow Follow MRSN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time